AIM VCTs company stories: Diaceutics
End-to-end solutions for the launch of precision medicine diagnostics.
Precision medicine diagnostics
Diaceutics provides data, data analytics and implementation services that enables the advancement of genetic analysis.
Diaceutics provides the world’s leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX – The Diagnostic Network®. The company generates insights from its aggregated testing data from its worldwide laboratory network. This provides real world evidence that informs the decision making of pharmaceutical companies across hundreds of precision medicine projects.
Octopus AIM VCT risks
Please remember that the value of an investment in the Octopus AIM VCTs, and any income from it, can fall as well as rise. Investors may not get back the full amount they invest.
Tax treatment depends on individual circumstances and may change in the future. Tax reliefs depend on the VCT maintaining its qualifying status.
VCT shares could fall or rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
Investors should only subscribe for shares on the basis of information contained in the prospectus and Key Information Documents (KIDs), available on the AIM VCT product page.
Contact our team
Got a question?
Call us at 0800 316 2067